The estimated Net Worth of A Blaine Bowman is at least $393 Mille dollars as of 1 May 2018. Mr. Bowman owns over 3,000 units of Personalis Inc stock worth over $118,215 and over the last 18 years he sold PSNL stock worth over $0. In addition, he makes $274,311 as Independent Director at Personalis Inc.
Sign up
Mr. Bowman PSNL stock SEC Form 4 insiders trading
A has made over 36 trades of the Personalis Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 3,000 units of PSNL stock worth $165,420 on 1 May 2018.
The largest trade he's ever made was exercising 5,000 units of Personalis Inc stock on 14 July 2016 worth over $214,100. On average, A trades about 2,511 units every 48 days since 2007. As of 1 May 2018 he still owns at least 19,868 units of Personalis Inc stock.
You can see the complete history of Mr. Bowman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
A. Blaine Bowman biography
A. Blaine Bowman serves as Independent Director of the Company. He served on the board of directors of Solexa, Inc., a DNA sequencing company, until its sale to Illumina, Inc., a biotechnology company, after which Mr. Bowman continued to serve on the board of directors until May 2018. From March 1977 to August 2005, Mr. Bowman served in various roles at Dionex Corporation, a manufacturer of analytical instruments, including Chairman of the board of directors, President, and Chief Executive Officer, and he served on the board of directors until its sale to Thermo Fisher Scientific Inc. in May 2011. From July 2012 to December 2015, Mr. Bowman served on the board of directors of Altera Corporation, a programmable logic devices company. Mr. Bowman holds a B.S. in Physics from Brigham Young University and an M.B.A. from the Stanford Graduate School of Business. Mr. Bowman was selected to serve on our board of directors because of his experience in executive roles and his experience serving on the boards of directors of various instrumentation and biotechnology companies.
What is the salary of A Bowman?
As the Independent Director of Personalis Inc, the total compensation of A Bowman at Personalis Inc is $274,311. There are 9 executives at Personalis Inc getting paid more, with Aaron Tachibana having the highest compensation of $3,003,510.
How old is A Bowman?
A Bowman is 73, he's been the Independent Director of Personalis Inc since 2019. There are no older and 16 younger executives at Personalis Inc.
What's A Bowman's mailing address?
A's mailing address filed with the SEC is C/O PERSONALIS, INC., 6600 DUMBARTON CIRCLE, FREMONT, CA, 94555.
Insiders trading at Personalis Inc
Over the last 5 years, insiders at Personalis Inc have traded over $56,423,548 worth of Personalis Inc stock and bought 5,708,990 units worth $54,066,334 . The most active insiders traders include Llp Abingworth, Paul Ricci e Ai, Inc. Tempus. On average, Personalis Inc executives and independent directors trade stock every 15 days with the average trade being worth of $410,996. The most recent stock trade was executed by Ai, Inc. Tempus on 16 August 2024, trading 3,500,000 units of PSNL stock currently worth $17,745,000.
What does Personalis Inc do?
personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.
What does Personalis Inc's logo look like?
Complete history of Mr. Bowman stock trades at Illumina Inc, Altair Engineering Inc e Personalis Inc
Personalis Inc executives and stock owners
Personalis Inc executives and other stock owners filed with the SEC include:
-
Aaron Tachibana,
Chief Financial Officer -
Clinton Musil,
Chief Business Officer -
John Stephen West,
Co-Founder, CEO, Pres & Director -
Paul Ricci,
Independent Director -
John West,
President, Chief Executive Officer, Director -
Dr. Richard Chen M.D., M.S., MS,
Sr. VP of R&D and Chief Medical Officer -
Richard Chen,
Chief Science Officer -
Aaron L. Tachibana,
Sr. VP & CFO -
Dr. Richard Chen M.S., M.D., MS,
Chief Scientific Officer -
A. Blaine Bowman,
Independent Director -
Alan Colowick,
Independent Director -
Karin Eastham,
Independent Director -
Jonathan MacQuitty,
Independent Chairman of the Board -
Kenneth Ludlum,
Independent Director -
Patrick Balthrop,
Independent Director -
Stephen Moore,
General Counsel -
Dr. Euan A. Ashley DPHIL, FRCP, M.D., Ph.D.,
Co-Founder and Member of Clinical & Scientific Advisory Board -
Prof. Russ B. Altman M.D., Ph.D.,
Co-Founder and Member of Clinical & Scientific Advisory Board -
Michael J. Fitzpatrick,
VP of Worldwide Sales -
Stephen M. Moore J.D.,
VP, Gen. Counsel & Corp. Sec. -
Carol J. Tillis,
VP of Fin. & Admin. -
Dr. Michael Snyder Ph.D.,
Co-Founder and Member of Clinical & Scientific Advisory Board -
Dr. Atul Butte,
Co-Founder and Member of Clinical & Scientific Advisory Board -
Dr. Euan A. Ashley M.D., Ph.D., FRCP, DPHIL,
Co-Founder and Member of Clinical & Scientific Advisory Board -
Prof. Russ B. Altman,
Co-Founder and Member of Clinical & Scientific Advisory Board -
Kenneth J Widder,
-
Olivia Kyusuk Bloom,
-
Ken Ludlum,
Director -
Mdv Partners, L.L.C.Mdv Ix ...,
-
Venture Partners Viii Lp Li...,
-
Venture Partners Select Iv,...,
-
Llp Abingworth,
-
Christopher M Hall,
PRESIDENT AND CEO -
Venture Partners Select Iv,...,
-
Ai, Inc. Tempus,
10% owner -
Lonnie Shoff,